Search results
Results from the WOW.Com Content Network
The Clinical Opiate Withdrawal Scale (COWS) is a method used by registered practitioners to measure the severity of a patient's opioid withdrawal symptoms. This method consists of a series of 11 topics each comprising 4–5 common symptoms experienced by a patient undergoing opioid withdrawal. In each topic a rank is given depending on what the ...
The Journal of Psychoactive Drugs is a peer-reviewed medical journal on psychoactive drugs. It was established in 1967 by David E. Smith and is currently published five times per year by Taylor & Francis. It was previously titled Journal of Psychedelic Drugs until 1980.
This study rated alcohol the most harmful drug overall, and the only drug more harmful to others than to the users themselves. [ 4 ] Alcohol withdrawal syndrome ( AWS ) is a set of symptoms that can occur following a reduction in or cessation of alcohol use after a period of excessive use. [ 1 ]
The severity of symptoms can be assessed by validated withdrawal scales, such as the Clinical Opiate Withdrawal Scale (COWS). [15] There is no test to diagnose for morphine withdrawal. [7] However, a toxicology test using urine is conducted to determine if withdrawal symptoms are caused by other non-opioid drugs or a combination of both. [7]
Drug use, including alcohol and prescription drugs, can induce symptomatology which resembles mental illness. This can occur both in the intoxicated state and during the withdrawal state. In some cases these substance-induced psychiatric disorders can persist long after detoxification from amphetamine, cocaine, opioid, and alcohol use, causing ...
Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption ...
MAPS officials say the organization's ultimate goal is to establish a network of clinics where these and other treatments can be provided together with other therapies under the guidance of trained, licensed physicians and therapists. [1] In December 2023, MAPS submitted a New Drug Application (NDA) to the FDA for MDMA-assisted psychotherapy. [2]
The system was developed for research purposes by the American biochemist Alexander Shulgin, and published with co-authors Ann Shulgin and Peyton Jacob, III, in a 1986 issue of the journal Methods and Findings in Experimental and Clinical Pharmacology. It was later described in the Shulgins' popular 1991 book PIHKAL: A Chemical Love Story. [1] [2]